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ABSTRACT
Objectives: to assess the diagnostic accuracy of quantitative parameters of DCE-
MRI in multi-parametric MRI (mpMRI) in comparison to the histopathology (including 
Gleason grade) of prostate cancer.
Patients and methods: 150 men with suspected prostate cancer (abnormal 
digital rectum examination and or elevated prostate-specific antigen) received pre-
biopsy 3T mpMRI and were recruited into peer-reviewed, protocol-based prospective 
study. The DCE-MRI quantitative parameters (Ktrans (influx transfer constant) and kep 
(efflux rate constant)) of the cancerous and normal areas were recorded using four 
different kinetic models employing Olea Sphere (Olea Medical, La Ciotat, France). The 
correlation between these parameters and the histopathology of the lesions (biopsy 
and in a sub-cohort 41 radical prostatectomy specimen) was assessed.
Results: The quantitative parameters showed a significant difference between 
non-cancerous (benign) and cancerous lesions (Gleason score≥3+3) in the prostate 
gland. The cut-off values for prostate cancer differentiation were: Ktrans (0.205 min-1) 
and kep (0.665 min-1) in the extended Tofts model (ET) and Ktrans(0.205 min-1 and kep 
(0.63 min-1) in the Lawrence and Lee delay (LD) models respectively. The mean Ktrans 
value also showed a difference between low-grade cancer (Gleason score=3+3) and 
high-grade cancer (Gleason score ≥ 3+4). With the addition of DCE-MRI quantitative 
parameters, the sensitivity of the PIRAD scoring system was increased from 56.6% 
to 92.1% (Ktrans_ET), 93.1% (kep_ET), 91.0%, (Ktrans_LD) and 89.4% (kep_LD).
Conclusion: Quantitative DCE-MRI parameters improved the diagnostic 
performance of conventional MRI in distinguishing normal and prostate cancers, 
including characterization of grade of cancers. The ET and LD models in post-image 
processing analysis provided better cut-off values for prostate cancer differentiation 
than the other quantitative DCE-MRI parameters.
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INTRODUCTION
Prostate cancer is the fifth leading cause of death 
from cancer in males (6.6% of total male deaths). An 
estimated 1.1 million men worldwide were diagnosed with 
prostate cancer (PCa) in 2012 (World Health Organization, 
GLOBOCAN 2012) [1]. Multi-parametric MRI (mpMRI) 
enables anatomical and molecular assessment of prostate 
cancers, including their cellularity and vascularity [2]. It 
has been suggested and widely used as a useful diagnostic 
modality for both localization and characterization of the 
PCa in many studies [2–9].
The mpMRI examination of the prostate typically 
consists of three stages, namely (i) anatomical imaging, 
(ii) tissue diffusion and (iii) tissue perfusion. The 
anatomy of the prostate and surrounding tissues can be 
visualized via the use of well-established qualitative 
MR techniques, such as T1-weighted (T1W) and T2-
weighted (T2W) images. Suspicions within the prostate 
in T2WI are often seen as subtle areas of hypo-intense 
signal relative to the surrounding healthy tissues. These 
anatomical assessments are supplemented by diffusion-
weighted imaging (DWI), which can probe the diffusion 
of extracellular and intracellular water molecules within 
the prostate tissues and highlight areas of low apparent 
diffusion coefficient (ADC), which may provide evidence 
for a diagnosis of prostate cancer [3]. In addition to 
DWI, gadolinium (Gd)-based techniques are also used 
to monitor the passage of a Gd contrast agent through 
the prostate tissues by dynamic contrast-enhanced MRI 
(DCE-MRI) [2]. The post-processing analysis of these 
images often studies semi-quantitative features associated 
with the contrast enhancement, such as the contrast up-
slope, time-to-peak enhancement, and so forth [10, 
11]. These assessments are included within the current 
radiological grading scheme for prostate cancer, which 
is the Prostate Imaging Reporting and Data System (PI-
RADS) scoring system. The PI-RADS is grounded on 
the five-grade Likert-like scale, evaluating the risk of 
clinically significant prostate cancer [12–14]. Although 
the semi-quantitative measures alone do not necessarily 
form clear-cut correlations with pathophysiologic features 
[4]. By examining the contrast wash-in and wash-out more 
quantitatively and by using pharmacokinetic modelling 
techniques, it is believed that the resulting indices may 
better reflect the microvascular properties within the tissue 
[10, 11]. Most studies in this area are from patients where 
MR imaging has been obtained after biopsies of prostate 
(with confirmed diagnosis) or histopathology of radical 
prostatectomy specimens are not aligned to imaging. 
There is no data or reported study on biopsy naïve prostate 
imaging, specifically using prospective protocol based 3T 
MR imaging. Moreover, validation data in which MRI 
sectioning of prostate alignment with histopathological 
processing using 3-D mold fabrication has not been 
reported.
In this study, we had the following objectives:
a) To prospectively assess the diagnostic accuracy of 
the quantitative parameters of DCE-MRI (mpMRI) 
in comparison to histopathology by independent 
observers in men with pre-biopsy imaging.
b) To establish “cut-off” values for pharmacokinetic 
parameters that may distinguish benign and cancerous 
prostate tissue, using a new post-processing analysis 
software algorithm.
RESULTS
Of the 150 patients recruited, pre-biopsy mpMRI 
was successfully performed in 138 patients. 12 patients 
ended up with incomplete or non-diagnostic MRI scans. 
Of those patients who completed the study, 1656 biopsy 
regions (12 regions x 138 patients) were analyzed. 
Positive TRUS-guided biopsy was identified in 26% of 
cases (n=431 regions), Gleason Score 3+3 were found in 
8.3% of all biopsy regions and Gleason score ≥ 3+4 were 
found in 17.7% of all biopsy regions. And the remaining 
74% (n=1225 regions) were TRUS-guided biopsy 
negative. In addition, 41 patients received prostatectomy, 
corresponding of all 492 histological regions (12 regions x 
41 patients) were analyzed. n=256 (52% of all histological 
regions) were deemed to be histologic negative. And n= 
236 (48% of all histological regions) were deemed to be 
histologic positive, which contains Gleason score = 3+3 
(n=12) and Gleason score ≥ 3+4 (n=224). A summary of 
these results can be found in Figure 1.
Biopsy histopathology results were initially used as 
the reference standard in the main cohort. The comparison 
between quantitative DCE parameters illustrates that Ktrans 
and kep have better diagnostic performance for PCa than ve 
and vp. Amongst the four models, the Extended Tofts (ET) 
and Lawrence & Lee delayed (LD) model had a higher 
area under curve than the other two models (Figure 2, 
Table 1); this indicates these two models provide better 
diagnostic performance in differentiating cancer from 
benign prostate tissue. Compared to the other two models, 
the mean Ktrans and kep values of the ET and LD models 
for the cancer and non-cancer groups also show a greater 
distinction. Thus, the Ktrans and kep cut-off values of the 
ET and LD models were selected separately as a DCE 
parameter grading system. The cut-off values of both 
models show high similarity.
T2 and DWI scores were analyzed by experienced 
radiology consultants. The sensitivity and specificity of 
the T2 and DWI scores for differentiating cancer and 
benign prostate tissue were 57.1%, 79.3% and 53.4%, 
80.1%, respectively. The combination of the T2 and DWI 
scores did not show any significant improvement. The 
sensitivity and specificity of the PI-RADS were similar to 
those of T2 and DWI. However, the addition of the DCE-
MRI parameter cut-off value to PI-RADS significantly 
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Figure 1: Flow of patients through the study.
Figure 2: The ROC curves of Ktrans and kep in four different kinetics models for performance in benign prostate 
tissue and PCa (Gleason score≥3+3).
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Table 1: Patients selection and baseline characteristics
Patients selection
Inclusion criteria Exclusion criteria
✓ Males between the age of 40-75 × Prior prostatic biopsy
✓ With at least 10 years’ life expectancy × Contraindication to biopsy
✓ Referred from primary care: × Poor general health and life expectancy < 10 years
● With clinically localised PCa: PSA>2.5 and <20 × Previous diagnosis of acute prostatitis× History of prostate cancer
● And/or abnormal DRE examination but <T3 disease × Prior transurethral prostatectomy
× Contraindication to MRI
× Contraindication to MRI
Patients characteristics
Patients number 150
Mean age (range) 62.5 (48-75)
Mean PSA level, ng/ml (range) 8.5 (2.7-20)
Mean prostate volume, cc (range) 58 (13-170)
Patients with incomplete DCE sequences (%) 12 (8%)
MRI negative patients (%) 30 (20%)
MRI positive patients (%) 108 (72%)
enhanced the sensitivity and specificity as the AUC value 
distinctly increased (Figure 3).
Further analysis using a histopathological map 
of radical prostatectomy specimen slices from 41 LRP 
patients as a second reference standard confirmed high 
AUC values of the models (Figure 4). The values of Ktrans 
and kep of the LD model showed increasing value, with a 
corresponding increase in the Gleason score obtained from 
histological analysis (Figure 5, pKtrans_LD=0.02, pkep_LD=0.01). 
In addition, the Ktrans of the LD model illustrated a relatively 
high two-tailed bivariate correlation coefficient (0.623) 
in comparison to the Gleason grade of histopathology 
obtained using molds fabricated with 3D printing.
DISCUSSION
Our study has shown a clear distinction of Ktrans 
and kep values between benign prostate tissue and 
prostate cancer (Gleason score≥3+3), similar to several 
previous studies [10, 15, 16]. Moreover, the Ktrans value 
of the LD model presents good performance accuracy 
in distinguishing low-grade PCa (Gleason score = 3+3) 
from high-grade PCa (Gleason score ≥ 3+4) disease 
(0.272 ± 0.107, 0.323 ± 0.145). This may explain why 
Ktrans has been considered to be the most cogent DCE 
quantitative parameter in many previous studies [2]. The 
findings of the present study, with imaging obtained in 
biopsy naive patients and further confirmation in radical 
prostatectomy specimens using patient-specific molds for 
histopathology analysis, adds further knowledge to our 
understanding. A few previous studies have focused on 
the semi-quantitative parameters in DCE-MRI [17, 18]. 
But the analysis of quantitative parameters in DCE-MRI 
provides the quantitative criterion as a reference rather 
than relying only on the shape of the DCE-curve, as is 
used for diagnosis of prostate cancer [15]. Many studies 
had shown the elevation of Ktrans, kep and ve in prostate 
cancer, as opposed to normal tissue [19–21]. The results 
of DCE-MRI quantitative parameters from many studies 
are summarized in Table 2. As can be seen, there is poor 
agreement regarding the cut-off values. Our results of the 
mean and cut-off value of Ktrans and kep are in agreement 
with some of the previous studies [10, 15, 16, 19–25]. 
For example, the result of the ET model is similar to that 
of Ocak et al [21]; the cut-off values show homogeneity 
with Echo et al [15]. Variations in cut-off values can 
be explained by many factors. The MRI scanners were 
produced by different manufacturers, different MRI 
parameters (time, resolution) during DCE-MRI were used, 
different patient groups with various stages of prostate 
cancer were studied, and most importantly, different post-
processing software algorithms for DCE-MRI were used. 
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Different software programs provide different models 
and algorithms for the DCE-MRI data. Even if the DCE-
MRI data is processed by the same model, two different 
software programs can generate different results, as well 
as Ktrans and kep maps. The ET model is widely used in 
many studies [15, 25].
Various studies have shown that the combination 
of T2, DWI and DCE-MRI can improve the detection of 
prostate cancer [2, 4]. The T2 and DWI scores showed 
a high specificity of prostate cancer differentiation, 
which represents the ability to correctly identify healthy 
people who do not have prostate cancer [26]; however, 
the sensitivity is relatively low, which means T2 and DWI 
alone may not be accurate in identifying patients with 
prostate cancer [27]. The combination of T2 and DWI 
scores did not improve the sensitivity and specificity. The 
Figure 3: The ROC curves of T2, DWI and PIRAD scoring system and the accession of DCE-MRI scoring system 
which based on the cut-off value of different parameters for benign prostate tissue and PCa (based on biopsy results).
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PI-RADS system also had similar diagnostic accuracy 
to T2 and DWI. However, with the addition of the DCE 
cut-off value to PI-RADS as a new grading system, the 
values of AUC increased by about 10% and the sensitivity 
was dramatically increased from 56.6% to 92.1%, 
93.1%, 91.0% and 89.4% for different models, without 
a significant decrease in specificity (78.6% to 54.3%, 
57.9%, 59.6% and 52.9% for different models). This 
strongly supports the diagnostic performance of the cut-
off value of quantitative DCE parameters, and suggests 
this grading system has increased diagnostic accuracy 
compared to the PI-RADS system.
The Gleason score obtained from the second 
reference standard also validated the diagnostic 
performance of this grading system. The histological 
results of whole-mount prostatectomy specimens are 
considered as the gold standard of PCa diagnosis with 
higher diagnostic accuracy than biopsy results. With 
this reference standard, the Gleason score obtained from 
TRUS-guided biopsy has sensitivity and specificity of 
Figure 4: The ROC curves and AUCs of the scoring system (PIRADS+DCE parameters) which used the Gleason score 
from histology (radical prostatectomy as reference standard).
Figure 5: The boxplots of Ktrans _LD and kep_LD showing performance in low grade vs. high grade prostate cancer.
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Table 2: MRI acquisition parameters
T1WI High resolution T2WI DWI DCE
Axial Sagittal Axial Coronal DWI DWI high b-value Dyn Gd-MRI
Sequence 2DTSE 2DTSE 2DTSE 2DTSE 2DEPI 2DEPI 3D VIBE
TR (ms) 650 6000 4000 5000 3300 3300 4.76
TE (ms) 11 102 100 100 95 95 2.45
Flip angle (°) 150 140 150 150 - - 10
Slice thickness 
(mm)
3 3 3 3 3 3 3
Slice gap (mm) 0.6 0.6 0.6 0.6 0 0 0.6
Resolution 
(pixels)
320 320 320 320 192 192 192
FOV (mm) 200 200 200 200 280 280 280
b-values (s/mm2) - - - - 50,100,500,1000 2000 -
Temporal 
resolution (s)
- - - - - - 4
Table 3: The mean and SD values of Ktrans and kep in four different kinetics models between benign prostate tissue and 
PCa (Gleason score≥3+3)
Tofts & Kermode Extended Tofts Lawrence & Lee Lawrence & Lee Delayed
Ktrans Kep Ktrans Kep Ktrans Kep Ktrans Kep
Mean, SD 
(min-1)
Non-cancer 0.65±0.52 1.84±1.46 0.27±0.35 0.72±0.66 0.19±0.17 0.6±0.64 0.19±0.17 0.67±0.74
cancer 0.98±0.44 2.57±1.29 0.53±0.44 1.33±0.74 0.29±0.14 0.85±0.44 0.31±0.14 0.99±0.50
Area under curve 0.690 0.645 0.736 0.754 0.728 0.674 0.749 0.698
Cut-off point (min-1) 0.495 1.295 0.205 0.665 0.195 0.47 0.205 0.63
Sensitivity & 
Specificity
91.6%, 
48.0%
88.0%, 
43.2%
81.7%,  
60.1%
88.0%, 
62.8%
73.8%, 
66.1%
89.0%, 
47.8%
78.0%, 
67.2%
79.6%, 
61.7%
p value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
The cut-off is exported with the sensitivity and specificity.
57.3% and 76.9% (p<0.001). This may be due to the 
fact that TRUS-guided biopsy has poor performance 
in sampling from anteriorly located tumors, as well as 
posteriorly located tumors in the peripheral zone [28]. The 
inhomogeneity of the tumor can also lead to a reduction in 
the biopsy’s accuracy.
There are several key differences between the 
present study and the reported literature. Firstly, four 
different pharmacokinetic models from the same software 
were used and compared; the cut-off values of the ET and 
LD models were chosen due to their higher sensitivity 
and specificity and both of them have shown similarity 
with some other studies. Secondly, in a subgroup of 
the cohort, we used our recently published method of 
providing improved orientation between radiological data 
and histopathology slides using patient-specific prostate 
molds [28], which is believed to have a higher diagnostic 
accuracy. All men in this study had pre-biopsy 3T MRI 
scanning which avoids any potential artefacts due to 
biopsies.
In addition to above, present study has limitation. 
Biopsy accuracy needs to be improved with more state-
of-art techniques, e.g. shear wave elastography, MRI 
fused imaging and multiple-plane imaging transducers. 
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Table 4: Literature review illustrating heterogeneity in cut-off values [10, 15, 17, 22-28]
MRI scanner Post-processing Ktrans(min-1) Kep (min-1)
Tesla Manufacturer Software Model Benign Cancer Cut-off Benign Cancer Cut-off
Kozlowski 
P et al. 1.5T GE Healthcare Mat lab TK 0.60 1.26 - - - -
Ocak l 
et al. 3T
Philips Medical 
systems
PRIDE 
software, 
Philips
TK 0.23 0.47 - 0.80 1.40 -
Dorston FA 
et al. 1.5T Siemens - Larsson 0.34 0.59 - 0.89 1.48 -
Li C et al 3T Philips Medical systems IDL 6.3 ET 0.09 0.32 - 0.72 1.44 -
Schlemmer 
et al. 1T Siemens
VAX alpha 
3000/500 Brix - - - 0.98 2.75 -
E Cho 
et al. 3T Siemens
Tissue 4D 
(Siemens) ET 0.09 0.38 0.184 0.57 1.64 0.695
Padhani 
AR et al. 1.5T Siemens MRIW ET 0.22 0.79 - 0.26 0.45 -
Langer Dl 
et al. 1.5T GE Healthcare Mat lab TK 0.298 0.253 - - - -
Peng Y 
et al. Philips Mat lab ET - - 0.257 - - -
Fusco R 
et al. 1.5T Siemens Mat lab ET - - 0.14 - - -
Our study 3T Siemens Olea Sphere ET 0.64 0.99 0.205 1.83 2.58 0.625
LD 0.18 0.31 0.205 0.68 0.99 0.63
Figure 6: Schematic description of the study, (a) T2WI, ADC map and MRI report from MRI examination with marked lesion in black 
circle, any suspicious lesions had PI-RADS 3 or above were marked. (in 138 patients). (b) DCE-MRI quantitative parameters map in Olea. 
The prostate was divided in 12 regions based on TRUS-guided biopsy cores, any regions contains suspicious lesions in MRI were marked 
(black circle) in Olea based on the MRI report and the regions without the lesions were marked across the whole area of regions. Then 
the quantitative DCE data of each region can be obtained. (c) The 12-core TRUS-guided biopsy report, the Gleason score obtained from 
each biopsy region can be compared with the quantitative parameters data (1656 biopsy regions). (d) Histopathology photographs were 
considered as another reference standard of Gleason score for the verification of the comparison between quantitative DCE data and biopsy 
reports. The Gleason score obtained from each histological region can be compared with the quantitative DCE data as well. 41 patients had 
the histological reports after received laparoscopic radical prostatectomy. (492 histological regions).
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DCE-MRI parameters need to validate with these biopsy 
techniques. Centre observation needs further external 
validity including cut-off values described. Research needs 
to focus areas such as selection and follow-up of men 
opting for active surveillance using quantitative DCE-MRI 
parameters as there was clear distinction between findings 
of high vs. low grade cancers atleast in two models.
MATERIALS AND METHODS
Patient recruitment
Between February 2015 and March 2017, 150 
patients with suspected localized prostate cancer were 
recruited into a peer-reviewed protocol-based prospective 
study (Figure 1). Inclusion criteria, exclusion criteria 
and baseline characteristics are summarized in Table 3. 
The prostate volumes were calculated using the formula 
for a conventional ellipse: maximum diameters of axial 
× transverse × longitudinal × 0.52 [13]. All participants 
received a pre-biopsy MRI. The MRI images were 
reported by an experienced radiologist (MB) and were 
used to guide DCE-MRI data analysis using MRI post-
processing software.
MR protocol
All MR images were carried out on 3T scanner 
(TIM Trio, Siemens, Erlangen, Germany). MR imaging 
was accomplished 1-2 weeks before 12 core transrectal 
ultrasound (TRUS) guided biopsies. The mpMRI 
protocol was derived from the European Society of Uro-
radiology Guidelines 2012 for the detection of prostate 
cancer and subsequent publication of version 2 [13, 
14]. Table 4 briefly summarizes the MRI acquisition 
parameters. Localizer images were acquired in all three 
imaging planes, where the plane of the prostate was 
defined in relation to the rectal wall. All subsequent 
images were acquired in the sagittal, axial or coronal 
oblique orientations relative to the anatomy of the 
prostate for each individual (Table 4). All patients were 
given 1 mL of Hyoscine Butylbromide (Buscopan), 20 
mg/mL intravenously prior to MRI, in order to eradicate 
movement associated with the bowel and rectum in the 
vicinity of the prostate. The DCE images were obtained 
using a 3D volume interpolated breath-hold examination 
(VIBE) gradient echo sequence, with a spine array and 
18 channel body-matrix RF coils (Siemens, Erlangen, 
Germany). The temporal resolution of each volume 
acquisition was 5.1 seconds and 50 measurements were 
acquired in total – giving a complete scan time of 4 
minutes and 15 seconds. The contrast agent gadoteric 
acid (Dotarem©, Guerbet, Villepinte, France) was 
administered after the completion of two ‘baseline’ 
measurements as a volume of 2ml/kg and at a rate of 
2ml/second using a Medrad Spectris Solaris EP injector 
pump (Bayer AG, Leverkusen, Germany). A saline 
bolus of 20ml was subsequently infused at a rate of 2ml/
second following the contrast agent infusion.
Image and histopathology data accrual and 
analysis
Data acquisition was performed in four stages, 
namely: (i) initial radiological scoring by experienced 
uro-radiologists (using T2, DWI and DCE qualitative), (ii) 
pharmacokinetic modelling assessment from DCE-MRI, 
(iii) TRUS biopsy analysis and (iv) the histology report of 
radical prostatectomy in 41 men (Figure 6).
Initial MRI scoring
The mpMRI images were analyzed and scored 
by experienced uro-radiologists using PI-RADS v2.0; 
all patients’ pathology results were blinded to the 
radiologist. At least two radiologists read the images (one 
in multidisciplinary meetings) with good inter-observer 
agreement. Suspicious lesions which had a PI-RADS score 
of 3 or above were marked. The size and extent of the 
lesions identified as suspicious for prostate cancer were 
recorded.
DCE-MRI data analysis
The quantitative parameters were analyzed using 
different pharmacokinetic models, in accordance with the 
principle that the contrast agent moves to the extravascular 
space [10]. The transfer from plasma to extravascular 
extracellular space (EES), which is the vascular 
permeability, can be obtained through the movement of the 
contrast agent [11]. The quantitative parameters include: 
Ktrans (influx transfer constant), Kep (efflux rate constant), 
ve (fractional volume of EES) and Vp (fractional volume 
of plasma space). The flux moves from the intravascular 
space to the EES depending on Ktrans. The efflux rate 
constant is the ratios of the influx transfer constant to the 
fractional volume of EES, which these two parameters are 
all related to the fundamental physiology [11].
The DCE-MRI data were analyzed using advanced 
MRI post-processing software, Olea Sphere (Olea Medical, 
La Ciotat, France). Based on the MRI report, the regions of 
interest (ROI) were marked on the DCE-MR images in Olea 
Sphere v2.3. For all the regions with suspicious lesions, 
ROIs were drawn around the lesion. In the regions without 
suspicious lesions, ROIs were drawn around the whole 
area. The MRI time-signal enhancement curves in each 
voxel were fitted in accordance with a pharmacokinetic 
model. In Olea Sphere, motion correction was performed 
automatically at first. Following that, four different models 
(Tofts & Kermode, extended Tofts, Lawrence & Lee, 
Lawrence & Lee Delayed) could be selected; the first two 
models (TK, ET) were widely used in clinical areas, while 
the other two models (LL, LD) have been used for research. 
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After the model was selected, the color map of various 
parameters was automatically computed. Hence, for each 
region, and four quantitative parameters (Ktrans, kep, ve, vp) 
of each modelwere calculated and obtained.
The prostate MRI images were divided into 12 
regions to correlate with the standard 12-core TRUS 
guided biopsy (right upper lateral, right base, right mid 
lateral, right para midline, right low lateral, right apex, left 
upper lateral, left base, left mid lateral, left para midline, 
left lower lateral, left apex). All regions with or without 
suspicious lesions inside the areas were analyzed and 
compared with the 12-core TRUS guided biopsy results 
for the whole cohort and in a sub-cohort histopathology of 
radical prostatectomy specimen.
TRUS biopsy data
The biopsy results were analyzed by experienced 
pathologists; who were each blinded to radiology results. 
The location and size of the core, the Gleason score and 
the degree of core involvement were acquired. Given this 
information, the quantitative DCE-MRI results of each 
region could be compared to the biopsy results.
Histopathology of radical prostatectomy specimens 
(validation cohort)
This was carried out only on a subset of the 
cohort. 41 patients who underwent laparoscopic radical 
prostatectomy (LRP); the radical prostate specimens 
for histology were sliced in patient-specific molds, 
which were fabricated using a 3D printer. In the process 
of sectioning, a single blade was applied carefully to 
prevent the friction and shifting of the specimen. Then 
all the sections were photographed and analyzed by 
pathologists. The technique has been described by 
us previously [28]. The histopathology map of each 
section was then compared with the MRI images and 
post-processing analysis. The histopathology maps 
were divided into 12 regions as described in an earlier 
approach for TRUS biopsies. The Gleason score 
obtained from the histopathology were used as a second 
reference standard for the validation of the results from 
the biopsy findings.
Statistical analysis
All analyses were performed using the Statistical 
Package for Social Science (SPSS) software (version 22). 
The values of quantitative DCE-MRI parameters were 
compared with histopathology. The differences between 
mean and standard deviation (SD) values of quantitative 
parameters in normal and prostate cancer were calculated. 
Receiver-operator-characteristic (ROC) curves were 
performed for the evaluation of diagnostic performance 
of the DCE parameters. Area under curve (AUC), 
sensitivity and specificity of each ROC curve were also 
calculated. Based on these values, the Youden index could 
be obtained. The point with the highest Youden index was 
extracted from the ROC curves as the cut-off point, which 
was determined to be the most accurate value for prostate 
cancer differentiation. The differences of quantitative 
parameters between low-grade PCa (Gleason score=3+3) 
and high-grade PCa (Gleason score ≥ 3+4) were calculated 
as well. A p-value of <0.05 was considered significant.
CONCLUSIONS
In conclusion, quantitative DCE-MRI parameters 
improve the diagnostic performance of MRI in 
distinguishing normal prostate tissue from prostate cancer 
and its various grades. The cut-off values of Ktrans and kep 
of the ET and LD models were defined, which could act 
as potential markers of the disease.
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